The use of Valeriana officinalis (Valerian) in improving sleep in patients who are undergoing treatment for cancer: a phase III randomized, placebo-controlled, double-blind study (NCCTG Trial, N01C5).
Quick navigation
Link to full study
http://www.ncbi.nlm.nih.gov/pubmed/21399726
Conclusion of this study
This study failed to provide data to support the hypothesis that valerian, 450 mg, at bedtime could improve sleep as measured by the PSQI. However, exploratory analyses revealed improvement in some secondary outcomes, such as fatigue. Further research with valerian exploring physiologic effects in oncology symptom management may be warranted.
Supplements analyzed in this study
Health conditions analyzed in this study
Functions related to this study
Body systems related to this study